BioSpace5h
Vertex Awaits FDA Verdict on Landmark Non-Opioid Pain Drug
Suzetrigine is an orally available pain signal inhibitor that selectively targets the NaV1.8 voltage-gated sodium channel, a genetically validated pain target found on peripheral neurons. NaV1.8 is ...
STAT5h
Cargo to lay off staff after CAR-T data show safety concerns
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, today we look at ...
Investors who Lost Money on Vertex Pharmaceuticals Incorporated Should Contact Levi & Korsinsky About an Ongoing Investigation - VRTX
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Fintel on MSN7h
Wells Fargo Downgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...
Vertex Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansion
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...